Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days
Black Diamond Therapeutics (Nasdaq: BDTX) announced that its President and CEO, David M. Epstein, Ph.D., will present an overview of the company's MasterKey programs, including BDTX-1535 and BDTX-4933, during the Stifel 2023 Targeted Oncology Days on April 25, 2023, at 11:00 a.m. ET. The presentation will take place virtually, and a live webcast can be accessed on the company's investor relations website. Following the event, a replay will be available for 90 days.
Black Diamond is a clinical-stage precision oncology medicine company, focused on developing MasterKey therapies that target oncogenic mutations in genetically defined cancers. Their lead programs include BDTX-1535 for EGFR mutant-positive non-small cell lung cancer and glioblastoma multiforme, and BDTX-4933 targeting RAF mutations in solid tumors. The company uses its proprietary MAP drug discovery engine to analyze genetic data and validate MasterKey mutations.
- None.
- None.
CAMBRIDGE, Mass. and NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision oncology medicine company developing MasterKey therapies designed to overcome limitations of existing therapies by targeting families of oncogenic driver mutations in patients with genetically defined cancers, today announced that its President and Chief Executive Officer, David M. Epstein, Ph.D., will present an overview of the Company’s MasterKey programs, including BDTX-1535 and BDTX-4933, at the Stifel 2023 Targeted Oncology Days on Tuesday, April 25, 2023, at 11:00 a.m. ET, being held virtually.
A live webcast of the presentation can be accessed by visiting the investors relations section of the Company’s website at: www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.
About Black Diamond
Black Diamond Therapeutics is a clinical-stage precision oncology medicine company focused on the development of MasterKey therapies that target families of oncogenic mutations in clinically validated targets. Black Diamond leverages a deep understanding of cancer genetics and onco-protein structure and function, to discover and develop innovative MasterKey therapies. The Company’s MasterKey therapies are designed to overcome resistance, minimize on-target, wild-type mediated toxicities, and be brain penetrant to address significant unmet medical needs of patients with genetically defined cancers. The Company is advancing a robust pipeline with lead clinical-stage program BDTX-1535, targeting MasterKey mutations in both EGFR mutant-positive non-small cell lung cancer (NSCLC) and in glioblastoma multiforme (GBM), and BDTX-4933, a program targeting RAF MasterKey mutations in solid tumors, as well as discovery-stage research programs. The Company’s proprietary Mutation-Allostery-Pharmacology, or MAP drug discovery engine, is designed to allow Black Diamond to analyze population-level genetic sequencing tumor data and validate MasterKey mutations.
Contact:
Julie Seidel, Stern Investor Relations
(212) 362-1200
investors@bdtx.com
media@bdtx.com
FAQ
What are Black Diamond Therapeutics' upcoming presentation details?
Where can I watch the Black Diamond Therapeutics presentation?
What is the focus of Black Diamond Therapeutics' MasterKey therapies?
What are the lead programs of Black Diamond Therapeutics?
What innovative approach does Black Diamond Therapeutics use for drug discovery?
